A Bayesian Decision Approach for Sample Size Determination in Phase II Trials

Stallard (1998, Biometrics54, 279–294) recently used Bayesian decision theory for sample-size determination in phase II trials. His design maximizes the expected financial gains in the development of a new treatment. However, it results in a very high probability (0.65) of recommending an ineffectiv...

Full description

Saved in:
Bibliographic Details
Main Authors: LEUNG, Denis H. Y., WANG, You-Gan
Format: text
Language:English
Published: Institutional Knowledge at Singapore Management University 2001
Subjects:
Online Access:https://ink.library.smu.edu.sg/soe_research/32
https://ink.library.smu.edu.sg/context/soe_research/article/1031/viewcontent/BaynesianDecisionPhaseII_2001.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Singapore Management University
Language: English
id sg-smu-ink.soe_research-1031
record_format dspace
spelling sg-smu-ink.soe_research-10312018-02-14T06:34:45Z A Bayesian Decision Approach for Sample Size Determination in Phase II Trials LEUNG, Denis H. Y. WANG, You-Gan Stallard (1998, Biometrics54, 279–294) recently used Bayesian decision theory for sample-size determination in phase II trials. His design maximizes the expected financial gains in the development of a new treatment. However, it results in a very high probability (0.65) of recommending an ineffective treatment for phase III testing. On the other hand, the expected gain using his design is more than 10 times that of a design that tightly controls the false positive error (Thall and Simon, 1994, Biometrics50, 337–349). Stallard's design maximizes the expected gain per phase II trial, but it does not maximize the rate of gain or total gain for a fixed length of time because the rate of gain depends on the proportion of treatments forwarding to the phase III study. We suggest maximizing the rate of gain, and the resulting optimal one-stage design becomes twice as efficient as Stallard's one-stage design. Furthermore, the new design has a probability of only 0.12 of passing an ineffective treatment to phase III study. 2001-01-01T08:00:00Z text application/pdf https://ink.library.smu.edu.sg/soe_research/32 info:doi/10.1111/j.0006-341X.2001.00309.x https://ink.library.smu.edu.sg/context/soe_research/article/1031/viewcontent/BaynesianDecisionPhaseII_2001.pdf http://creativecommons.org/licenses/by-nc-nd/4.0/ Research Collection School Of Economics eng Institutional Knowledge at Singapore Management University Bayesian Decision theory Gain function Gittins Index Sample size Sequential design Econometrics Medicine and Health Sciences
institution Singapore Management University
building SMU Libraries
continent Asia
country Singapore
Singapore
content_provider SMU Libraries
collection InK@SMU
language English
topic Bayesian
Decision theory
Gain function
Gittins Index
Sample size
Sequential design
Econometrics
Medicine and Health Sciences
spellingShingle Bayesian
Decision theory
Gain function
Gittins Index
Sample size
Sequential design
Econometrics
Medicine and Health Sciences
LEUNG, Denis H. Y.
WANG, You-Gan
A Bayesian Decision Approach for Sample Size Determination in Phase II Trials
description Stallard (1998, Biometrics54, 279–294) recently used Bayesian decision theory for sample-size determination in phase II trials. His design maximizes the expected financial gains in the development of a new treatment. However, it results in a very high probability (0.65) of recommending an ineffective treatment for phase III testing. On the other hand, the expected gain using his design is more than 10 times that of a design that tightly controls the false positive error (Thall and Simon, 1994, Biometrics50, 337–349). Stallard's design maximizes the expected gain per phase II trial, but it does not maximize the rate of gain or total gain for a fixed length of time because the rate of gain depends on the proportion of treatments forwarding to the phase III study. We suggest maximizing the rate of gain, and the resulting optimal one-stage design becomes twice as efficient as Stallard's one-stage design. Furthermore, the new design has a probability of only 0.12 of passing an ineffective treatment to phase III study.
format text
author LEUNG, Denis H. Y.
WANG, You-Gan
author_facet LEUNG, Denis H. Y.
WANG, You-Gan
author_sort LEUNG, Denis H. Y.
title A Bayesian Decision Approach for Sample Size Determination in Phase II Trials
title_short A Bayesian Decision Approach for Sample Size Determination in Phase II Trials
title_full A Bayesian Decision Approach for Sample Size Determination in Phase II Trials
title_fullStr A Bayesian Decision Approach for Sample Size Determination in Phase II Trials
title_full_unstemmed A Bayesian Decision Approach for Sample Size Determination in Phase II Trials
title_sort bayesian decision approach for sample size determination in phase ii trials
publisher Institutional Knowledge at Singapore Management University
publishDate 2001
url https://ink.library.smu.edu.sg/soe_research/32
https://ink.library.smu.edu.sg/context/soe_research/article/1031/viewcontent/BaynesianDecisionPhaseII_2001.pdf
_version_ 1770569011005751296